# An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor

> **NCT01231568** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 28 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Regimen A
- **DRUG:** Regimen B
- **DRUG:** Regimen C
- **DRUG:** Regimen D

## Key facts

- **NCT ID:** NCT01231568
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-21
- **Primary completion:** 2011-05-13
- **Final completion:** 2011-05-13
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2017-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01231568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01231568, "An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01231568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*